Rheumatoid Arthritis: Baricitinib more effective than adalimumab

Nature Reviews Rheumatology 13, 197 (2017). doi:10.1038/nrrheum.2017.32 Author: Jessica McHugh Treatment with baricitinib, an orally administered inhibitor of Janus kinases 1 and 2, improved clinical features in patients with active RA and an inadequate response to methotrexate, and was more effective than adalimumab or placebo. 70% of patients treated with 4mg baricitinib daily achieved an
Source: Nature Reviews Rheumatology - Category: Rheumatology Authors: Tags: Research Highlight Source Type: research